| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Paul S Hoffman | |
| Gina Devasahayam | |||
| William M Scheld | |||
| P2860 | cites work | Functional, biophysical, and structural bases for antibacterial activity of tigecycline | Q24548264 |
| In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci | Q24550612 | ||
| Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus | Q24556635 | ||
| A cholesterol biosynthesis inhibitor blocks Staphylococcus aureus virulence | Q24650591 | ||
| Genome sequencing of linezolid-resistant Streptococcus pneumoniae mutants reveals novel mechanisms of resistance | Q24655140 | ||
| Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet(M)- and Tet(O)-mediated ribosomal protection | Q24675249 | ||
| Carbapenemases: the versatile beta-lactamases | Q24685034 | ||
| Structural basis for the antibiotic activity of ketolides and azalides | Q27640646 | ||
| A nuclear receptor-like pathway regulating multidrug resistance in fungi | Q27650217 | ||
| An inhibitor of FtsZ with potent and selective anti-staphylococcal activity | Q27652237 | ||
| Increased hydrophobic interactions of iclaprim with Staphylococcus aureus dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity | Q27653751 | ||
| Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori | Q28205159 | ||
| The diarylquinoline TMC207 for multidrug-resistant tuberculosis | Q28247333 | ||
| Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial | Q28250954 | ||
| The highly conserved LepA is a ribosomal elongation factor that back-translocates the ribosome | Q28274472 | ||
| Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response | Q28298985 | ||
| Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates | Q28374993 | ||
| Drugs for bad bugs: confronting the challenges of antibacterial discovery | Q29547723 | ||
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies | Q29617810 | ||
| Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni | Q30442308 | ||
| The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data | Q30998307 | ||
| Targeting bacterial virulence: inhibitors of type III secretion in Yersinia | Q31137077 | ||
| Ketolide resistance in Streptococcus pyogenes correlates with the degree of rRNA dimethylation by Erm. | Q33224241 | ||
| Nitazoxanide for the treatment of Clostridium difficile colitis | Q33250018 | ||
| Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections | Q33321478 | ||
| Safety and tolerability of linezolid | Q33347872 | ||
| Targeting QseC signaling and virulence for antibiotic development | Q33362330 | ||
| Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections | Q33416170 | ||
| Comparative in vitro activities of XRP 2868, pristinamycin, quinupristin-dalfopristin, vancomycin, daptomycin, linezolid, clarithromycin, telithromycin, clindamycin, and ampicillin against anaerobic gram-positive species, actinomycetes, and lactobac | Q33555811 | ||
| Oxazolidinone resistance mutations in 23S rRNA of Escherichia coli reveal the central region of domain V as the primary site of drug action. | Q33787419 | ||
| In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). | Q33976567 | ||
| Antipneumococcal activity of ABT-773 compared to those of 10 other agents | Q33980037 | ||
| Binding site of macrolide antibiotics on the ribosome: new resistance mutation identifies a specific interaction of ketolides with rRNA | Q33997135 | ||
| Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA beta-lactam antibiotics | Q34012457 | ||
| Isolating "uncultivable" microorganisms in pure culture in a simulated natural environment | Q34127944 | ||
| In vitro activity of OPT-80 against Clostridium difficile | Q34142125 | ||
| Cross-linking in the Living Cell Locates the Site of Action of Oxazolidinone Antibiotics | Q34189984 | ||
| Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria | Q34277300 | ||
| Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections | Q34372966 | ||
| Glycylcyclines: third-generation tetracycline antibiotics | Q34476155 | ||
| Dihydrofolate reductase inhibitors as antibacterial agents | Q34477235 | ||
| Streptococcus pneumoniae isolates resistant to telithromycin | Q34648611 | ||
| Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis | Q34720793 | ||
| AcrAB multidrug efflux pump is associated with reduced levels of susceptibility to tigecycline (GAR-936) in Proteus mirabilis | Q34822277 | ||
| Ketolides: the future of the macrolides? | Q34904894 | ||
| Activity of the anti-MRSA carbapenem razupenem (PTZ601) against Enterobacteriaceae with defined resistance mechanisms | Q34985016 | ||
| In vitro activity of TR-700, the active ingredient of the antibacterial prodrug TR-701, a novel oxazolidinone antibacterial agent | Q34986954 | ||
| In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae | Q35123976 | ||
| In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species | Q35132865 | ||
| Why is big Pharma getting out of antibacterial drug discovery? | Q35565576 | ||
| In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci | Q35647735 | ||
| Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar typhimurium | Q40124075 | ||
| Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines | Q40285942 | ||
| Immunomodulatory clarithromycin treatment of experimental sepsis and acute pyelonephritis caused by multidrug-resistant Pseudomonas aeruginosa | Q40410604 | ||
| Inactivation of antibiotics and the dissemination of resistance genes | Q40737331 | ||
| Antistaphylococcal activity of dalbavancin, an experimental glycopeptide | Q41005410 | ||
| AcrAB efflux pump plays a role in decreased susceptibility to tigecycline in Morganella morganii | Q41005771 | ||
| Bacterial resistance to vancomycin: five genes and one missing hydrogen bond tell the story | Q41112839 | ||
| In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. | Q41389487 | ||
| In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457. | Q41788543 | ||
| Bactericidal activity and resistance development profiling of dalbavancin | Q41839607 | ||
| Activity of a new oral streptogramin, XRP2868, against gram-positive cocci harboring various mechanisms of resistance to streptogramins | Q41859834 | ||
| Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. | Q42049579 | ||
| In vitro activity of ceftaroline alone and in combination against clinical isolates of resistant gram-negative pathogens, including beta-lactamase-producing Enterobacteriaceae and Pseudomonas aeruginosa | Q42111661 | ||
| Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin | Q42112713 | ||
| In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections | Q42444666 | ||
| In vitro activity of NXL104 in combination with beta-lactams against Klebsiella pneumoniae isolates producing KPC carbapenemases | Q42577530 | ||
| Interactions of ceftobiprole with beta-lactamases from molecular classes A to D. | Q42584480 | ||
| A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae | Q42664352 | ||
| Improved virologic response in chronic hepatitis C genotype 4 treated with nitazoxanide, peginterferon, and ribavirin | Q42984385 | ||
| Selection for high-level telithromycin resistance in Staphylococcus aureus yields mutants resulting from an rplB-to-rplV gene conversion-like event | Q43063841 | ||
| Affinity of doripenem and comparators to penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa | Q43111763 | ||
| Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin | Q43298146 | ||
| Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria | Q43553034 | ||
| Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study | Q43694841 | ||
| In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta-lactamases | Q43750721 | ||
| Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium. | Q43834023 | ||
| The ketolide antibiotic ABT-773 is a specific inhibitor of translation and 50S ribosomal subunit formation in Streptococcus pneumoniae cells | Q44102832 | ||
| Clinical experience with linezolid for the treatment of nocardia infection | Q44285699 | ||
| Linezolid-associated toxic optic neuropathy: a report of 2 cases | Q44635723 | ||
| Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria | Q44803993 | ||
| Doripenem (S-4661), a novel carbapenem: comparative activity against contemporary pathogens including bactericidal action and preliminary in vitro methods evaluations | Q44931240 | ||
| Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens | Q45237058 | ||
| Treatment of intestinal parasitic infections: a review of nitazoxanide | Q45712771 | ||
| Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. | Q45981762 | ||
| Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin | Q46259630 | ||
| Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms | Q46476490 | ||
| Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens | Q46515797 | ||
| Effect of clarithromycin in patients with sepsis and ventilator-associated pneumonia | Q46620649 | ||
| The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam | Q46634329 | ||
| Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study | Q46672001 | ||
| Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections | Q46758156 | ||
| Population pharmacokinetic analysis of dalbavancin, a novel lipoglycopeptide | Q46765999 | ||
| A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections | Q46787486 | ||
| Telithromycin and the FDA: implications for the future | Q46789591 | ||
| Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003). | Q46819792 | ||
| Will longer antimicrobial patents improve global public health? | Q51103968 | ||
| Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936. | Q54093262 | ||
| Microbiology. Desperately seeking new antibiotics. | Q54416539 | ||
| Neospora caninum: functional inhibition of protein disulfide isomerase by the broad-spectrum anti-parasitic drug nitazoxanide and other thiazolides. | Q54435596 | ||
| The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria. | Q54441462 | ||
| Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by beta-lactamases. | Q54620636 | ||
| Ketolides lack inducibility properties of MLS(B) resistance phenotype | Q73568566 | ||
| The role of hydrophobic side chains as determinants of antibacterial activity of semisynthetic glycopeptide antibiotics | Q73743262 | ||
| In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic | Q78207198 | ||
| Anti-infective antibodies: finding the path forward | Q79423608 | ||
| In vitro efficacy of Linezolid on clinical strains of Mycobacterium tuberculosis and other mycobacteria | Q79480417 | ||
| Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus | Q79760369 | ||
| The oxazolidinone class of drugs find their orientation on the ribosome | Q80390129 | ||
| Physicochemical properties of antibacterial compounds: implications for drug discovery | Q80662325 | ||
| Novel beta-lactam antibiotics and inhibitor combinations | Q80822934 | ||
| A comparison of a new oral streptogramin XRP 2868 with quinupristin-dalfopristin against antibiotic-resistant strains of haemophilus influenzae, Staphylococcus aureus, and Streptococcus pneumoniae | Q81407693 | ||
| Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study | Q94701669 | ||
| A novel Giardia lamblia nitroreductase, GlNR1, interacts with nitazoxanide and other thiazolides | Q35840867 | ||
| Efflux-mediated antimicrobial resistance | Q36138147 | ||
| The antimicrobial armamentarium: evaluating current and future treatment options | Q36264494 | ||
| Gallbladder cancer worldwide: geographical distribution and risk factors | Q36362499 | ||
| Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America | Q36382134 | ||
| Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. | Q36422630 | ||
| Telithromycin resistance in Streptococcus pneumoniae is conferred by a deletion in the leader sequence of erm(B) that increases rRNA methylation | Q36425045 | ||
| Clinical and economic impact of common multidrug-resistant gram-negative bacilli | Q36482801 | ||
| Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus | Q36512904 | ||
| Emerging bacterial enzyme targets | Q36747327 | ||
| Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis | Q36803956 | ||
| Targeting virulence: a new paradigm for antimicrobial therapy | Q36914994 | ||
| The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis | Q36954404 | ||
| New oxazolidinones | Q36967558 | ||
| Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection | Q37032807 | ||
| Cell-division inhibitors: new insights for future antibiotics | Q37103616 | ||
| Helicobacter Pylori associated global gastric cancer burden. | Q37125644 | ||
| P1A recombinant beta-lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampicillin | Q37204242 | ||
| Antivirulence as a new antibacterial approach for chemotherapy | Q37221247 | ||
| Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa | Q37333121 | ||
| In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae | Q37867274 | ||
| Studies of the novel ketolide ABT-773: transport, binding to ribosomes, and inhibition of protein synthesis in Streptococcus pneumoniae | Q39474079 | ||
| In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria | Q39474756 | ||
| In vitro activities of linezolid against multiple Nocardia species | Q39477004 | ||
| Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibil | Q39478313 | ||
| Comparison of in vitro activities of ABT-773 and telithromycin against macrolide-susceptible and -resistant streptococci and staphylococci | Q39652894 | ||
| In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci | Q39685988 | ||
| In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in Staphylococcus aureus | Q39686067 | ||
| In vitro activity of telavancin against resistant gram-positive bacteria | Q39686121 | ||
| Dimerization and membrane anchors in extracellular targeting of vancomycin group antibiotics | Q39779438 | ||
| Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic | Q39782968 | ||
| Molecular interactions of a semisynthetic glycopeptide antibiotic with D-alanyl-D-alanine and D-alanyl-D-lactate residues | Q39783431 | ||
| The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin | Q39785029 | ||
| Genetics and mechanisms of glycopeptide resistance in enterococci | Q39866365 | ||
| Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa | Q39894808 | ||
| Intracellular bacterial growth is controlled by a kinase network around PKB/AKT1. | Q40043123 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 215-234 | |
| P577 | publication date | 2010-02-01 | |
| P1433 | published in | Expert Opinion on Investigational Drugs | Q5421208 |
| P1476 | title | Newer antibacterial drugs for a new century | |
| P478 | volume | 19 |
| Q40075272 | A Review on Antibiotic Resistance: Alarm Bells are Ringing |
| Q33660699 | A Thiazole Orange Derivative Targeting the Bacterial Protein FtsZ Shows Potent Antibacterial Activity |
| Q21131155 | A brief history of the antibiotic era: lessons learned and challenges for the future |
| Q41965799 | Acanthamoeba and bacteria produce antimicrobials to target their counterpart. |
| Q37916805 | Advances in antibacterial therapy |
| Q37726760 | Animals living in polluted environments are potential source of antimicrobials against infectious agents |
| Q52714219 | Antibacterial activity of 3-methylbenzo[d]thiazol-methylquinolinium derivatives and study of their action mechanism. |
| Q91633835 | Antimicrobial activity of bacteria from marine sponge Suberea mollis and bioactive metabolites of Vibrio sp. EA348 |
| Q47727124 | Application of Nanoparticle Technologies in the Combat against Anti-Microbial Resistance |
| Q35791501 | Architecture and conservation of the bacterial DNA replication machinery, an underexploited drug target |
| Q37955948 | Bacterial type I signal peptidases as antibiotic targets |
| Q84405067 | Bactericidal activity identified in 2S Albumin from sesame seeds and in silico studies of structure-function relations |
| Q54375154 | Burden of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay associated with bloodstream infections due to Escherichia coli resistant to third-generation cephalosporins. |
| Q33793074 | Challenges of antibacterial discovery |
| Q36633761 | Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. |
| Q36850184 | Detection of secreted antimicrobial peptides isolated from cell-free culture supernatant of Paenibacillus alvei AN5. |
| Q38055325 | Development of new drugs for an old target: the penicillin binding proteins. |
| Q53731399 | Drug design based on pentaerythritol tetranitrate reductase: synthesis and antibacterial activity of Pogostone derivatives. |
| Q55386605 | Epidemiology of multi-drug resistant organisms in a teaching hospital in oman: a one-year hospital-based study. |
| Q28649661 | Evaluation of regional antibiograms to monitor antimicrobial resistance in Hampton Roads, Virginia |
| Q36029187 | High-throughput screening for RecA inhibitors using a transcreener adenosine 5'-O-diphosphate assay |
| Q40506281 | Identification and characterization of antibacterial compound(s) of cockroaches (Periplaneta americana). |
| Q34389235 | In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline |
| Q46967782 | Isolation and identification of a new intracellular antimicrobial peptide produced by Paenibacillus alvei AN5. |
| Q37857331 | Linezolid, the first oxazolidinone antibacterial agent |
| Q41870937 | LpxC Inhibitors: Design, Synthesis, and Biological Evaluation of Oxazolidinones as Gram-negative Antibacterial Agents |
| Q65000980 | New application of tiplaxtinin as an effective FtsZ-targeting chemotype for an antimicrobial study. |
| Q34488329 | Newer antibacterials in therapy and clinical trials |
| Q34903245 | Novel classes of antibiotics or more of the same? |
| Q91738612 | Novel phthalimide based analogues: design, synthesis, biological evaluation, and molecular docking studies |
| Q39616901 | Novel systemic antibiotics in dermatology |
| Q26995797 | Phage cocktails and the future of phage therapy |
| Q38778154 | Research and development of antibiotics: insights from patents and citation network. |
| Q27678160 | Restoring methicillin-resistant Staphylococcus aureus susceptibility to β-lactam antibiotics |
| Q41290532 | Structure-activity relationships and molecular docking studies of chromene and chromene based azo chromophores: A novel series of potent antimicrobial and anticancer agents |
| Q42612662 | Suppressive drug combinations and their potential to combat antibiotic resistance. |
| Q30276966 | Synthesis and Antimicrobial Evaluation of Amixicile-Based Inhibitors of the Pyruvate-Ferredoxin Oxidoreductases of Anaerobic Bacteria and Epsilonproteobacteria |
| Q37796156 | The future of the β-lactams. |
| Q40763094 | Thioridazine inhibits gene expression control of the cell wall signaling pathway (CWI) in the human pathogenic fungus Paracoccidioides brasiliensis. |
Search more.